BR0313723A - Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor - Google Patents
Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptorInfo
- Publication number
- BR0313723A BR0313723A BR0313723-6A BR0313723A BR0313723A BR 0313723 A BR0313723 A BR 0313723A BR 0313723 A BR0313723 A BR 0313723A BR 0313723 A BR0313723 A BR 0313723A
- Authority
- BR
- Brazil
- Prior art keywords
- beta
- agonist activity
- compounds
- adrenoreceptor agonist
- benzothiazole derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0218629A GB0218629D0 (en) | 2002-08-09 | 2002-08-09 | Organic compounds |
GB0220955A GB0220955D0 (en) | 2002-09-10 | 2002-09-10 | Organic compounds |
PCT/EP2003/008824 WO2004016601A1 (en) | 2002-08-09 | 2003-08-08 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0313723A true BR0313723A (pt) | 2005-08-02 |
Family
ID=31889675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0313723-6A BR0313723A (pt) | 2002-08-09 | 2003-08-08 | Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor |
Country Status (22)
Country | Link |
---|---|
US (3) | US20060106075A1 (pt) |
EP (1) | EP1529038B1 (pt) |
JP (1) | JP4541145B2 (pt) |
KR (1) | KR20070064687A (pt) |
AR (1) | AR040962A1 (pt) |
AT (1) | ATE444958T1 (pt) |
AU (1) | AU2003255400B2 (pt) |
BR (1) | BR0313723A (pt) |
CA (1) | CA2493765C (pt) |
DE (1) | DE60329601D1 (pt) |
EC (1) | ECSP055582A (pt) |
ES (1) | ES2331879T3 (pt) |
IL (1) | IL166334A0 (pt) |
MX (1) | MXPA05001613A (pt) |
NO (1) | NO20051165L (pt) |
NZ (1) | NZ538021A (pt) |
PE (1) | PE20050130A1 (pt) |
PL (1) | PL374314A1 (pt) |
PT (1) | PT1529038E (pt) |
RU (1) | RU2324687C2 (pt) |
TW (1) | TW200408630A (pt) |
WO (1) | WO2004016601A1 (pt) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20050130A1 (es) * | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
ATE435855T1 (de) | 2003-11-21 | 2009-07-15 | Theravance Inc | Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0402797D0 (en) * | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
JP5138362B2 (ja) | 2004-03-23 | 2013-02-06 | ノバルティス アーゲー | 医薬組成物 |
US7307076B2 (en) | 2004-05-13 | 2007-12-11 | Boehringer Ingelheim International Gmbh | Beta agonists for the treatment of respiratory diseases |
CA2565243A1 (en) * | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases |
GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
GB0411056D0 (en) * | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
US20080039495A1 (en) | 2004-06-03 | 2008-02-14 | Linsell Martin S | Diamine Beta2 Adrenergic Receptor Agonists |
EP1778638A1 (en) | 2004-07-21 | 2007-05-02 | Theravance, Inc. | Diaryl ether beta2 adrenergic receptor agonists |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) * | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
US7411093B2 (en) * | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
DE102005007654A1 (de) * | 2005-02-19 | 2006-08-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
US7994211B2 (en) | 2005-08-08 | 2011-08-09 | Argenta Discovery Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
TW200740781A (en) * | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
JP5006330B2 (ja) | 2005-10-21 | 2012-08-22 | ノバルティス アーゲー | Il13に対するヒト抗体および治療的使用 |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
TW200745084A (en) * | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
AR060607A1 (es) | 2006-04-21 | 2008-07-02 | Novartis Ag | Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias. |
GB0613154D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
US20090286779A1 (en) | 2006-09-29 | 2009-11-19 | Novartis Ag | Pyrazolopyrimidines as lipid kinase inhibitors |
CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
TW200833670A (en) * | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
AU2007336074B2 (en) * | 2006-12-20 | 2011-09-22 | Astrazeneca Ab | Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases |
ATE493174T1 (de) | 2007-01-10 | 2011-01-15 | Irm Llc | Verbindungen und zusammensetzungen als kanal- aktivierende proteasehemmer |
GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
US20100239551A1 (en) | 2007-02-09 | 2010-09-23 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
GB0704000D0 (en) * | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | Salts 670 |
ES2361595T3 (es) | 2007-05-07 | 2011-06-20 | Novartis Ag | Compuestos orgánicos. |
CN101939054B (zh) | 2007-12-10 | 2014-10-29 | 诺华股份有限公司 | 有机化合物 |
BRPI0906838A2 (pt) | 2008-01-11 | 2015-07-14 | Novartis Ag | Pirimidinas como inibidores de quinase |
KR20110040818A (ko) | 2008-06-10 | 2011-04-20 | 노파르티스 아게 | 상피 나트륨 채널 차단제로서의 피라진 유도체 |
AU2009260899B2 (en) | 2008-06-18 | 2012-02-23 | Astrazeneca Ab | Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders |
UY31920A (es) * | 2008-06-20 | 2010-01-29 | Astrazeneca Ab | Nueva combinacion-408 |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
US8362064B2 (en) | 2008-12-30 | 2013-01-29 | Pulmagen Theraputics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
US20110281917A1 (en) | 2009-01-29 | 2011-11-17 | Darrin Stuart | Substituted Benzimidazoles for the Treatment of Astrocytomas |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
GEP201706639B (en) | 2009-08-17 | 2017-03-27 | Intellikine Llc | Heterocyclic compounds and uses thereof |
IN2012DN01453A (pt) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
CN102665715A (zh) | 2009-10-22 | 2012-09-12 | 沃泰克斯药物股份有限公司 | 治疗囊性纤维化和其他慢性疾病的组合物 |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
JP5959541B2 (ja) | 2011-02-25 | 2016-08-02 | ノバルティス アーゲー | Trk阻害剤としてのピラゾロ[1,5−a]ピリジン |
GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
JP5886433B2 (ja) | 2011-09-16 | 2016-03-16 | ノバルティス アーゲー | 嚢胞性線維症処置のためのヘテロ環式化合物 |
EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
ES2894830T3 (es) | 2012-04-03 | 2022-02-16 | Novartis Ag | Productos combinados con inhibidores de tirosina·cinasa y su uso |
SI2890687T1 (sl) | 2012-08-30 | 2017-10-30 | Novartis Ag | Soli benzotiazolonske spojine kot agonist beta-2-adrenoceptorja |
DK2961391T3 (en) | 2013-02-28 | 2017-09-04 | Novartis Ag | Formulation comprising a benzothiazolone compound |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
MX2016013983A (es) | 2014-04-24 | 2017-04-06 | Novartis Ag | Derivados de pirazina como inhibidores de fosfatidil-inositol-3-ci nasa. |
US10004732B2 (en) | 2014-04-24 | 2018-06-26 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2015162456A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
ES2831416T3 (es) | 2014-07-31 | 2021-06-08 | Novartis Ag | Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR |
US10227305B2 (en) | 2014-08-22 | 2019-03-12 | G. Pratap REDDY | Process for preparing indacaterol and salts thereof |
AU2016209930A1 (en) | 2015-01-20 | 2017-07-13 | Novartis Ag | Application unlock using a connected physical device and transfer of data therebetween |
ES2897697T3 (es) | 2015-07-03 | 2022-03-02 | Novartis Ag | Inhalador adaptado para leer información almacenada en un medio de almacenamiento de datos de un recipiente |
JP2022537667A (ja) | 2019-06-10 | 2022-08-29 | ノバルティス アーゲー | Cf、copd、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体 |
EP4021572A1 (en) | 2019-08-28 | 2022-07-06 | Novartis AG | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
CR20230125A (es) | 2020-08-14 | 2023-05-11 | Novartis Ag | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4091218A (en) * | 1975-12-29 | 1978-05-23 | Texaco Development Corporation | Morpholine process |
GB9211172D0 (en) * | 1992-05-27 | 1992-07-08 | Fisons Plc | Compounds |
US5648370A (en) * | 1990-11-20 | 1997-07-15 | Astra Pharmaceuticals Limited | 7-(2-aminoethyl) benzothiazolones |
GB9405019D0 (en) * | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
TW356468B (en) * | 1995-09-15 | 1999-04-21 | Astra Pharma Prod | Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same |
GB9526511D0 (en) * | 1995-12-23 | 1996-02-28 | Astra Pharma Prod | Pharmaceutically active compounds |
WO1999009018A1 (fr) * | 1997-08-14 | 1999-02-25 | Kirin Beer Kabushiki Kaisha | DERIVES DE BENZOTHIAZOLONE PRESENTANT UNE ACTIVITE SELECTIVE D'AGONISTE DU RECEPTEUR β2 |
JP2002509119A (ja) * | 1998-01-13 | 2002-03-26 | アストラゼネカ ユーケイ リミテッド | ドーパミン(D2)レセプターアゴニスト活性を有する化合物およびβ2−アドレナリンレセプターアゴニスト活性を有する化合物(B)を含有する薬学的組成物 |
SE9903995D0 (sv) * | 1999-11-03 | 1999-11-03 | Astra Ab | New combination |
TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
PE20050130A1 (es) * | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
EP1622875B1 (en) * | 2003-05-08 | 2009-12-02 | Theravance, Inc. | Crystalline forms of an arylaniline beta-2 adrenergic receptor agonist |
WO2005080375A1 (en) * | 2004-02-13 | 2005-09-01 | Theravance, Inc. | Crystalline form of a biphenyl compound |
US7569586B2 (en) * | 2004-08-16 | 2009-08-04 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
GB0426164D0 (en) * | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0613154D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
-
2003
- 2003-08-07 PE PE2003000791A patent/PE20050130A1/es not_active Application Discontinuation
- 2003-08-07 AR ARP030102843A patent/AR040962A1/es unknown
- 2003-08-08 ES ES03787754T patent/ES2331879T3/es not_active Expired - Lifetime
- 2003-08-08 WO PCT/EP2003/008824 patent/WO2004016601A1/en active IP Right Grant
- 2003-08-08 NZ NZ538021A patent/NZ538021A/en unknown
- 2003-08-08 US US10/522,359 patent/US20060106075A1/en not_active Abandoned
- 2003-08-08 PT PT03787754T patent/PT1529038E/pt unknown
- 2003-08-08 MX MXPA05001613A patent/MXPA05001613A/es active IP Right Grant
- 2003-08-08 BR BR0313723-6A patent/BR0313723A/pt not_active IP Right Cessation
- 2003-08-08 DE DE60329601T patent/DE60329601D1/de not_active Expired - Lifetime
- 2003-08-08 PL PL03374314A patent/PL374314A1/xx not_active Application Discontinuation
- 2003-08-08 RU RU2005106846/04A patent/RU2324687C2/ru not_active IP Right Cessation
- 2003-08-08 JP JP2004528453A patent/JP4541145B2/ja not_active Expired - Fee Related
- 2003-08-08 EP EP03787754A patent/EP1529038B1/en not_active Expired - Lifetime
- 2003-08-08 AU AU2003255400A patent/AU2003255400B2/en not_active Ceased
- 2003-08-08 KR KR1020077012943A patent/KR20070064687A/ko not_active Application Discontinuation
- 2003-08-08 CA CA2493765A patent/CA2493765C/en not_active Expired - Fee Related
- 2003-08-08 AT AT03787754T patent/ATE444958T1/de not_active IP Right Cessation
- 2003-08-08 TW TW092121840A patent/TW200408630A/zh unknown
-
2005
- 2005-01-17 IL IL16633405A patent/IL166334A0/xx unknown
- 2005-01-27 EC EC2005005582A patent/ECSP055582A/es unknown
- 2005-03-04 NO NO20051165A patent/NO20051165L/no not_active Application Discontinuation
-
2007
- 2007-06-27 US US11/823,622 patent/US20070249586A1/en not_active Abandoned
-
2014
- 2014-11-06 US US14/534,708 patent/US20150065490A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1529038B1 (en) | 2009-10-07 |
ATE444958T1 (de) | 2009-10-15 |
CA2493765A1 (en) | 2004-02-26 |
KR20070064687A (ko) | 2007-06-21 |
AU2003255400B2 (en) | 2007-06-07 |
PE20050130A1 (es) | 2005-03-29 |
US20150065490A1 (en) | 2015-03-05 |
ES2331879T3 (es) | 2010-01-19 |
US20070249586A1 (en) | 2007-10-25 |
PT1529038E (pt) | 2009-11-24 |
JP2005539027A (ja) | 2005-12-22 |
IL166334A0 (en) | 2006-01-16 |
RU2324687C2 (ru) | 2008-05-20 |
TW200408630A (en) | 2004-06-01 |
EP1529038A1 (en) | 2005-05-11 |
RU2005106846A (ru) | 2006-01-10 |
US20060106075A1 (en) | 2006-05-18 |
CA2493765C (en) | 2010-09-28 |
AU2003255400A1 (en) | 2004-03-03 |
AR040962A1 (es) | 2005-04-27 |
NZ538021A (en) | 2007-12-21 |
DE60329601D1 (de) | 2009-11-19 |
JP4541145B2 (ja) | 2010-09-08 |
PL374314A1 (en) | 2005-10-03 |
MXPA05001613A (es) | 2005-08-19 |
WO2004016601A1 (en) | 2004-02-26 |
ECSP055582A (es) | 2005-04-18 |
NO20051165L (no) | 2005-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0313723A (pt) | Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor | |
BRPI0410037A (pt) | inibidores da fosfatidilinositol 3-cinase | |
BR9910849A (pt) | Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido. | |
BR0308784A (pt) | Miméticos de glucocorticóides, métodos para fabricar os mesmos, composições farmacêuticas e usos dos mesmos | |
BR0214177A (pt) | Derivado de benzofenona, agente preventivo ou terapêutico para uma doença em que está envolvida expressão excessiva de ap-1, e, inibidor de ap-1 | |
BRPI0708038B8 (pt) | derivado de cumarina, composição farmacêutica e agente terapêutico para um distúrbio proliferativo celular | |
BR0010555A (pt) | Inibidores de neuraminidases | |
BR0313160A (pt) | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto | |
BRPI0311323B8 (pt) | composto inibidor de c-aril glicosídeo sglt2, composição farmacêutica e combinação | |
BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
BR0211122A (pt) | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal | |
BRPI0806318B8 (pt) | sacarídeo capsular modificado, processo para modificar um sacarídeo, conjugado proteína sacarídea, molécula e composição farmacêutica | |
BRPI0518231A2 (pt) | derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica | |
BR0211118A (pt) | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal | |
BR0210711A (pt) | Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto | |
BRPI0517894A (pt) | derivados de 5-hidróxi-benzo tiazol possuindo atividade agonista de adrenorreceptor beta-2 | |
BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
BR0206381A (pt) | Derivados do ácido fumárico como inibidor de nf-kappab | |
BR0314071A (pt) | Derivados de pró-droga de 1,3-diamino-2-hidroxipropano | |
BRPI0606793A8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica | |
NO20053775L (no) | Diazepinoindol derivater som kinaseinhibitorer. | |
BRPI0607433A2 (pt) | composto ou um sal do mesmo, pró-droga, agente farmacêutico, inibidor de peptidase, uso de um composto ou de uma pró-droga do mesmo, e, métodos de prevenção ou tratamento de doenças, de inibição de peptidase em um mamìfero, e de produção de um composto | |
BRPI0312398B8 (pt) | derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído | |
BR0210874A (pt) | Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: A61K 31/428, A61K 31/4545, A61K 31/55, A61K 31/4523, A61K 45/00, C07D 277/68, C07D 417/12, A61P 11/00, A61P 11/02, A61P 11/06, A61P 11/08, A61P 17/00, A61P 17/06, A61P 27/14, A61P 29/00, A61P 37/08 Ipc: C07D 277/68 (2011.01), C07D 417/12 (2011.01), A61K |
|
B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES. |
|
B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |